EUVIMEDEUVIMED entdecken
Crossref

Blocking of IL‐4/IL‐13 Signalling With Dupilumab Results in Restoration of Serum and Cutaneous Abnormalities in Netherton Syndrome

Stefan Blunder iD, Natascha Hermann-Kleiter iD, Rita Mahmuti, Martin Hermann iD, Daniela Ortner, Daniela Reider, Verena Moosbrugger-Martinz, Barbara Del Frari iD, Patrizia Stoitzner iD, Sandrine Dubrac iD, Matthias Schmuth iD, Robert Gruber iD

Experimental Dermatology · 2025

DOI: 10.1111/exd.70113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, 2025. Verfasst von Stefan Blunder und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergy, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Netherton Syndrome, Antibodies, Monoclonal, Humanized, Interleukin-13, Interleukin-4. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: clinician scientist research fellowship grant from the Austrian Society for Dermatology and Venereology (ÖGDV), Medical Research fund Tyrol (MFF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Netherton syndrome (NS) is a rare ichthyosis caused by SPINK5‐ null mutations, resulting in erythroderma, ichthyosis linearis circumflexa, and atopic diathesis. Elevated serum IgE levels and activation of the KLK5‐PAR2‐TSLP axis suggest involvement of Th2‐skewed immunity in NS. In this pilot study, we investigated the effects of IL‐4/IL‐13 blocking with dupilumab on NS features. At baseline, Th2‐chemokines CCL11, CCL17, CCL18, CCL26, and serum IgE were more elevated in atopic dermatitis (AD) than in NS vs. controls (ctrls). AD exhibited elevated serum levels of CCL27, LDH, and eosinophils, while NS showed higher levels of IL‐9 and IL‐18. Epidermal aberrations, including acanthosis and SC‐detachment, were present in NS versus ctrls. The number of CD3+ T cells increased, while CD1a + Langerhans cell numbers decreased in NS skin. Amounts of KLK5 were reduced, and the distribution of KLK7 was abnormal in NS epidermis as compared to ctrls. Reduced amounts of FLG, CDSN, and DSG1 highlight impaired keratinocyte late differentiation in NS. Amounts of epidermal TSLP were diminished. Upon dupilumab treatment, clinical improvement in NS began as early as week 8 and continued up to 30 months, with no serious side effects reported. Serum levels of IgE, CCL17, CCL26, IFN‐γ and IL‐18 decreased upon IL‐4/IL‐13 blockade, and alterations of cutaneous immune cells improved in NS. Furthermore, the epidermal protease inhibitor WFDC12 expression increased after dupilumab treatment, concurring with improved and partially normalised epidermal structure, including increased FLG, CDSN, and DSG1. These data highlight Th2‐skewed immunity in NS and emphasise the amelioration of NS features through dupilumab treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Netherton SyndromeAntibodies, Monoclonal, HumanizedInterleukin-13Interleukin-4HumansMaleDermatitis, AtopicFemaleSerine Peptidase Inhibitor Kazal-Type 5Pilot ProjectsImmunoglobulin EAdultSignal TransductionFilaggrin ProteinsKallikreinsChildAdolescentYoung AdultChild, Preschool

Stichwörter der Autor:innen

IL‐4/IL‐13 blockadeNetherton syndromedupilumabepidermal differentiationichthyosis

Substanzen

Antibodies, Monoclonal, HumanizedInterleukin-13dupilumabInterleukin-4SPINK5 protein, humanSerine Peptidase Inhibitor Kazal-Type 5IL4 protein, humanImmunoglobulin EFilaggrin ProteinsKallikreins

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Allergy, Medical University of Innsbruck, Innsbruck, Austria.
  • Institute of Cell Genetics, Department for Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Anaesthesiology and Critical Care Medicine, Medical University of Innsbruck, Innsbruck, Austria.
  • Departmtent of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Innsbruck, Innsbruck, Austria.

ORCID-Profile: Stefan Blunder, Natascha Hermann-Kleiter, Martin Hermann, Barbara Del Frari, Patrizia Stoitzner, Sandrine Dubrac, Matthias Schmuth, Robert Gruber

Förderung

  • clinician scientist research fellowship grant from the Austrian Society for Dermatology and Venereology (ÖGDV)
  • Medical Research fund Tyrol (MFF)

Zitieren

APA

Blunder, S., Hermann-Kleiter, N., Mahmuti, R., Hermann, M., Ortner, D., Reider, D., Moosbrugger-Martinz, V., Del Frari, B., Stoitzner, P., Dubrac, S., Schmuth, M., & Gruber, R. (2025). Blocking of IL‐4/IL‐13 Signalling With Dupilumab Results in Restoration of Serum and Cutaneous Abnormalities in Netherton Syndrome. Experimental Dermatology. https://doi.org/10.1111/exd.70113

Vancouver

Blunder S, Hermann-Kleiter N, Mahmuti R, Hermann M, Ortner D, Reider D, et al. Blocking of IL‐4/IL‐13 Signalling With Dupilumab Results in Restoration of Serum and Cutaneous Abnormalities in Netherton Syndrome. Experimental Dermatology. 2025. doi:10.1111/exd.70113

BibTeX
@article{Blunder2025,
  author = {Blunder, Stefan and Hermann-Kleiter, Natascha and Mahmuti, Rita and Hermann, Martin and Ortner, Daniela and Reider, Daniela and Moosbrugger-Martinz, Verena and Del Frari, Barbara and Stoitzner, Patrizia and Dubrac, Sandrine and Schmuth, Matthias and Gruber, Robert},
  title = {Blocking of IL‐4/IL‐13 Signalling With Dupilumab Results in Restoration of Serum and Cutaneous Abnormalities in Netherton Syndrome},
  journal = {Experimental Dermatology},
  year = {2025},
  doi = {10.1111/exd.70113}
}
Kostenlos starten →